Skip to navigation Skip to content

Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised elotuzumab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma (MM).

For details on how to process a PBS Authority, see:

On this page:

Multiple myeloma (MM) quick reference - Initial and Balance of Supply

Multiple myeloma (MM) quick reference - Continuing and no treatment phase

Newly diagnosed triple therapy (21-day cycle for 8 cycles)

Newly diagnosed triple therapy (28-day cycle for 6 cycles)

Multiple myeloma (MM) quick reference - Initial and Balance of Supply

Table 1

Restrictions

Treatment type

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self- serve

Initial

Newly

diagnosed

PB291 form

Monotherapy

Written

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

Newly

diagnosed

PB200 form

Dual therapy with dexamethasone

Written

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

Newly diagnosed

PB293 form

Triple therapy (this drug, bortezomib and dexamethasone)

Written

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Balance of Supply

Newly diagnosed

(cycles 5-6 or cycles 5-8)

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

Progressive disease

PB158 form

Monotherapy or dual combination therapy with dexamethasone

Written

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

PB214

Dual therapy (this drug and dexamethasone)

Written

Electronic

S100:

pomalidomide

No

OPA

Not specified

Yes

Initial

Relapsed and/or refractory multiple myeloma

Dual therapy (this drug and dexamethasone)

Telephone

Electronic

S100:

selinexor

(general listing)

No

OPA

Not specified

Yes

Initial

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

pomalidomide

No

OPA

Not specified

Yes

Initial

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

selinexor

(general listing)

No

OPA

Not specified

Yes

Multiple myeloma (MM) quick reference - Continuing and no treatment phase

Table 2

Restrictions

Treatment type

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self- serve

Continuing

Progressive disease

Monotherapy or dual combination therapy with dexamethasone

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, elotuzumab and dexamethasone)

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, carfilzomib and dexamethasone)

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Continuing

Dual therapy (this drug and dexamethasone)

Telephone

Electronic

S100:

pomalidomide

No

OPA

Not specified

Yes

Continuing

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

pomalidomide

No

OPA

Not specified

Yes

Continuing

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, lenalidomide and dexamethasone)

Telephone

Electronic

S100 - EFC

elotuzumab. For commercial reasons as of 1 December 2024, initial treatment with elotuzumab as triple therapy is no longer PBS-subsidised. Continuing treatment with elotuzumab as triple therapy remains on the PBS to make sure continuity of the treatment for existing patients.

No

OPA

Not specified

Yes

Continuing

Relapsed and/or refractory multiple myeloma

Dual therapy (this drug and dexamethasone)

Telephone

Electronic

S100:

selinexor

(general listing)

No

OPA

Not specified

Yes

Continuing

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

selinexor

(general listing)

No

OPA

Not specified

Yes

Newly diagnosed triple therapy (21-day cycle for 8 cycles)

Table 3

Step

Treatment phase

Drug combination

Treatment cycle

Quantity & repeats

Authority level

1

Initial

lenalidomide & dexamethasone & bortezomib

Cycle 1 - 4
  • Quantity 14
  • Repeats 3

Written (PB293)

Electronic

2

Balance

lenalidomide & dexamethasone & bortezomib

Cycle 5 - 8
  • Quantity 14
  • Repeats 3

Telephone

Electronic

3

Continuing dual therapy (meeting criteria)

lenalidomide & dexamethasone

Cycle 9 and beyond
  • Quantity 21
  • Repeats 5

Telephone

Electronic

Newly diagnosed triple therapy (28-day cycle for 6 cycles)

Table 4

Step

Treatment phase

Drug combination

Treatment cycle

Quantity & repeats

Authority level

1

Initial

lenalidomide & dexamethasone & bortezomib

Cycle 1 - 4
  • Quantity 21
  • Repeats 3

Written (PB293)

Electronic

2

Balance

lenalidomide & dexamethasone & bortezomib

Cycle 5 - 6
  • Quantity 21
  • Repeats 1

Telephone

Electronic

3

If ineligible for SCT

Initial newly diagnosed dual therapy

If post SCT

Initial newly diagnosed monotherapy

Ineligible for SCT

lenalidomide & dexamethasone

Post SCT

lenalidomide

N/A

Ineligible for SCT

  • Quantity 21
  • Repeats 5

Post SCT

  • Quantity 28
  • Repeats 2

Ineligible for SCT

Written (PB200)

Electronic

Post SCT

Written (PB291)

Electronic